[go: up one dir, main page]

AU2003233964A1 - Use of compositions containing petasites for treating diseases - Google Patents

Use of compositions containing petasites for treating diseases

Info

Publication number
AU2003233964A1
AU2003233964A1 AU2003233964A AU2003233964A AU2003233964A1 AU 2003233964 A1 AU2003233964 A1 AU 2003233964A1 AU 2003233964 A AU2003233964 A AU 2003233964A AU 2003233964 A AU2003233964 A AU 2003233964A AU 2003233964 A1 AU2003233964 A1 AU 2003233964A1
Authority
AU
Australia
Prior art keywords
cox
extract
gen
fraction
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003233964A
Inventor
Reiner Rittinghausen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weber and Weber GmbH and Co KG
Original Assignee
Weber and Weber GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Weber and Weber GmbH and Co KG filed Critical Weber and Weber GmbH and Co KG
Publication of AU2003233964A1 publication Critical patent/AU2003233964A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/76—Salicaceae (Willow family), e.g. poplar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)

Abstract

The use of a Petasitesextract (and/or its fraction(s)) (A) for: (1) the production of a specific cyclooxygenase-2 (COX-2) inhibitor; (2) treatment and/or prophylaxis of diseases treatable by specific COX-2 inhibition; and/or (3) production of a spasmolytic and/or analgesic medicament. Independent claims are included for: (1) a Petasitesextract (and/or its fraction(s)) (A') which contains not more than 30 (preferably less than 0.001) wt. % petasine (I) (based on the solvent-free extract or extract fraction); (2) a specific COX-2 inhibitor based on (A) (in (I)-containing, (I)-depleted or (I)-free form); and (3) a composition based on (A) (in (I)-containing, (I)-depleted or (I)-free form), where (A) is a polar or apolar extract or is enriched with a polar and/or apolar extract. ACTIVITY : Analgesic; antiarthritic; osteopathic; antirheumatic; cytostatic; antiulcer; antiinflammatory; thrombolytic; cardiant; vasotropic; antianginal; cerebroprotective; neuroprotective; hypotensive; antimigraine; antiasthmatic; antiallergic; dermatological; nootropic; tuberculostatic; antipsoriatic; gynecological; tranquilizer; hypnotic; antidepressant; Gastrointestinal-Gen.; Cardiovascular-Gen.; Respiratory-Gen.; Uropathic. MECHANISM OF ACTION : COX-2 inhibitor.
AU2003233964A 2002-04-22 2003-04-11 Use of compositions containing petasites for treating diseases Abandoned AU2003233964A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10217939A DE10217939A1 (en) 2002-04-22 2002-04-22 Use of compositions containing petasites for the treatment of disease conditions
DE10217939.5 2002-04-22
PCT/EP2003/003756 WO2003088985A2 (en) 2002-04-22 2003-04-11 Use of compositions containing petasites for treating diseases

Publications (1)

Publication Number Publication Date
AU2003233964A1 true AU2003233964A1 (en) 2003-11-03

Family

ID=29224654

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003233964A Abandoned AU2003233964A1 (en) 2002-04-22 2003-04-11 Use of compositions containing petasites for treating diseases

Country Status (5)

Country Link
EP (2) EP1803462B1 (en)
AT (1) ATE370742T1 (en)
AU (1) AU2003233964A1 (en)
DE (2) DE10217939A1 (en)
WO (1) WO2003088985A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10311651A1 (en) * 2003-03-14 2004-09-23 Weber & Weber Gmbh & Co. Kg Acute treatment of pain, spasms and related disorders, e.g. migraine, asthma, colitis or depression, using petasins, furanopetasins, eremophilane lactones or Petasites extracts or their fractions
WO2006000119A1 (en) * 2004-06-23 2006-01-05 Max Zeller Soehne Ag Copd treatment and medicament
CN101028322B (en) * 2007-04-02 2011-08-03 中国人民解放军第二军医大学 Application of Butterbur pilaris Extract in the Preparation of Drugs for Preventing and Treating Tumor Diseases
WO2011042469A1 (en) * 2009-10-07 2011-04-14 Reiner Rittinghausen Use of a compound based on eremophilanolides
US8709501B1 (en) * 2011-07-22 2014-04-29 Beverly Jansen Method for treating wounds for mammals, wound healer compound, and method of manufacturing thereof
ES2811951T3 (en) 2015-04-01 2021-03-15 Zeller Max Soehne Ag Butterbur extract and composition to treat viral infections
CN105267836A (en) * 2015-09-03 2016-01-27 毕国风 Traditional Chinese medicine for treating coronary heart disease
EP3906040A1 (en) 2018-12-31 2021-11-10 Max Zeller Söhne AG Combination of cimicifuga and petasites extracts for anticancer therapy and prophylaxis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH660966A5 (en) * 1984-02-29 1987-06-30 Amo Pharm Ag Process for obtaining a petasites extract with high therapeutic activity from Petasites hybridus, with a content of from 60 to 75% petasin
EP0281656B1 (en) * 1987-03-12 1992-01-29 Plantamed Arzneimittel GmbH Use of petasite extracts in the preparation of a medicine for the treatment of gastrointestinal diseases
DE4002938C2 (en) * 1990-02-01 1998-08-13 Sueddeutsche Kalkstickstoff Process for the production of extracts from Rhizoma Petasitidis
DE4111141A1 (en) * 1991-04-06 1992-10-08 Sueddeutsche Kalkstickstoff METHOD FOR PRODUCING EXTRACTS FROM RHIZOMA PETASITIDIS
DE4141749A1 (en) * 1991-12-14 1993-06-17 Weber & Weber Gmbh METHOD FOR PRODUCING EXTRACTS FROM RHIZOMA PETASITIDIS
CH690355A5 (en) * 1996-03-28 2000-08-15 Zeller Max Soehne Ag Use of extract of Petasites hybridus and method and apparatus for the recovery of the extract.
EP0908185A1 (en) * 1997-10-13 1999-04-14 Max Zeller Söhne AG Process for the production of extracts from medicinal plants
DE19838848A1 (en) * 1998-08-26 2000-03-02 Weber & Weber Gmbh & Co Kg Composition containing pyrrolizidine alkaloid-free petasites

Also Published As

Publication number Publication date
EP1803462A3 (en) 2007-10-03
EP1803462A2 (en) 2007-07-04
WO2003088985A2 (en) 2003-10-30
DE10217939A1 (en) 2003-11-13
EP1803462B1 (en) 2017-11-01
DE50308005D1 (en) 2007-10-04
WO2003088985A8 (en) 2004-05-27
EP1499334A2 (en) 2005-01-26
ATE370742T1 (en) 2007-09-15
EP1499334B1 (en) 2007-08-22
WO2003088985A3 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
UA82980C2 (en) Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
WO2004037773A8 (en) Phenethanolamine derivative for the treatment of respiratory diseases
WO2004037768A3 (en) Phenethanolamine derivatives
AP2088A (en) Phenethanolamine derivatives for treatment of respiratory diseases
MY119155A (en) New peptide derivatives
DE59407237D1 (en) NITRATO-AMINO ACID DISULFIDES FOR THE THERAPY OF DISEASES OF THE HEART CIRCUIT SYSTEM
ATE337785T1 (en) TIOTROPIUM SALTS FOR THE TREATMENT OF INFLAMMATORY DISEASES
MXPA04002405A (en) Phenethanolamine derivatives for treatment of respiratory diseases.
AU2275397A (en) Troponin subunits and fragments useful as angiogenesis inhibitors
WO2003077860A3 (en) BOSWELLIN COMPOSITIONS ENHANCED WITH 3-β-ACETYL-11-KETO-β-BOSWELLIC ACID (“AKBA”), INDUSTRIAL MANUFACTURE AND THEIR USES
WO2001051044A3 (en) Substances for use in treating psoriasis
AU2003233964A1 (en) Use of compositions containing petasites for treating diseases
WO2006068768A3 (en) Methods and compositions for treating conditions
PL371205A1 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
EP0712844A4 (en) NEW CONDENSED CARBONIC ACID OR YOUR SALT AND YOUR MEDICAL USE
WO2003039453A3 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
BR9914184A (en) Reduction of oxidative strength factors
ATE336284T1 (en) COSMETIC USE OF PHYTANTRIOL AS AN AGENT FOR PREVENTING OR REDUCING THE ADDHESION OF MICROORGANISMS TO THE SURFACE OF THE SKIN AND/OR MUCOUS MEASURES.
AU4777293A (en) Control of wound scar production with calcium antagonists alone or in a combination with a steroid
PA8525801A1 (en) PIRAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS TO MODULATE AND / OR INHIBIT THE ACTIVITY OF ERAB / HADH2
NZ326345A (en) Composition containing diosgenin
EP1123692A3 (en) Use of polyaminoacid derivatives for the treatment of Seborrhea and related cutaneous disorders
ATE337005T1 (en) NAIL POLISH CONTAINING TAZAROTENE AND USE THEREOF FOR THE TREATMENT AND/OR PREVENTION OF PSORIASIS
WO2003084503A3 (en) P38 kinase inhibitors for treating mucus hypersecretion_
MXPA05001469A (en) Use of fermented wheat germ extract as anti-inflammatory agent.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase